Evidence map›Paper›PMID 23094098›Full record

ArticlePloS one2012

Alterations in white matter microstructure in neurofibromatosis-1.

Katherine H Karlsgodt, Tena Rosser, Evan S Lutkenhoff, Tyrone D Cannon, Alcino Silva, Carrie E Bearden

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04481035 phase2completednot on this mapstarted 2019, after this paper: background citation

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2019 to 2021Enrolled5ConditionsNeurofibromatosis 1ArmsN-acetylcysteine (NAC), Placebo
NCT04481048 phase2completednot on this mapstarted 2021, after this paper: background citation

Antioxidant Therapy With N-acetylcysteine for Motor Behavior and/or Learning in Children With Neurofibromatosis Type 1

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2021 to 2024Enrolled25ConditionsNeurofibromatosis 1ArmsN-Acetyl cysteine, Placebo
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. NF1Clinical and translational science · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Katherine H KarlsgodtSemel Institute for Neuroscience and Behavior, University of California Los Angeles, Los Angeles, California, United States of America. kkarlsgodt@nshs.edu
Tena Rosser
Evan S Lutkenhoff
Tyrone D Cannon
Alcino Silva
Carrie E Bearden
University of California, Los Angeles · USChildren's Hospital of Los Angeles · USUniversity of Southern California · US

Funding

Mechanisms for Neurological Dysfunction in NF1 and Noonan SyndromeR01MH084315 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SILVA, ALCINO J. · 2008 to 2020
$5.0M
Neurofibromatosis Type I as a Model for Therapeutic NeuroadaptationR34MH089299 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E · 2009 to 2011
$691k
NIMH NIH HHS MH084315NIMH NIH HHS R01 MH084315NIMH NIH HHS R34 MH089299NIMH NIH HHS R34 MH089299-01
6 · The paper itself

Abstract

Neurofibromatosis (NF1) represents the most common single gene cause of learning disabilities. NF1 patients have impairments in frontal lobe based cognitive functions such as attention, working memory, and inhibition. Due to its well-characterized genetic etiology, investigations of NF1 may shed light on neural mechanisms underlying such difficulties in the general population or other patient groups. Prior neuroimaging findings indicate global brain volume increases, consistent with neural over-proliferation. However, little is known about alterations in white matter microstructure in NF1. We performed diffusion tensor imaging (DTI) analyses using tract-based spatial statistics (TBSS) in 14 young adult NF1 patients and 12 healthy controls. We also examined brain volumetric measures in the same subjects. Consistent with prior studies, we found significantly increased overall gray and white matter volume in NF1 patients. Relative to healthy controls, NF1 patients showed widespread reductions in white matter integrity across the entire brain as reflected by decreased fractional anisotropy (FA) and significantly increased absolute diffusion (ADC). When radial and axial diffusion were examined we found pronounced differences in radial diffusion in NF1 patients, indicative of either decreased myelination or increased space between axons. Secondary analyses revealed that FA and radial diffusion effects were of greatest magnitude in the frontal lobe. Such alterations of white matter tracts connecting frontal regions could contribute to the observed cognitive deficits. Furthermore, although the cellular basis of these white matter microstructural alterations remains to be determined, our findings of disproportionately increased radial diffusion against a background of increased white matter volume suggest the novel hypothesis that one potential alteration contributing to increased cortical white matter in NF1 may be looser packing of axons, with or without myelination changes. Further, this indicates that axial and radial diffusivity can uniquely contribute as markers of NF1-associated brain pathology in conjunction with the typically investigated measures.

Indexed as

AdultAnisotropyAxonsCase-Control StudiesDiffusion Tensor ImagingFemaleFrontal LobeGyrus CinguliHumansMaleNeurofibromatosis 1Neurofibromin 1Organ SizeThalamusNeurofibromin 1

Identifiers

PMID23094098
PMCPMC3477133
OpenAlexW1997744354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.